Skip to content

Application of artificial intelligence based on deep learning in the diagnosis and treatment of age-related macular degeneration

Application of artificial intelligence based on deep learning in the diagnosis and treatment of age-related macular degeneration

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400093122
Enrollment
Unknown
Registered
2024-11-28
Start date
2023-12-01
Completion date
Unknown
Last updated
2024-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

age-related macular degeneration

Interventions

Modeling group:None
Conbercept group:None
Ranibizumab:None

Sponsors

Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 90 Years

Inclusion criteria

Inclusion criteria: a. The clinical diagnosis of patients diagnosed as AMD is based on visual acuity examination, fundus slit lamp examination, Oberger fundus photography, optical coherence tomography angiography (OCTA); b. Age from 50 to 90 years old, regardless of sex, all underwent macular OCTA 6*6mm examination; c. Macular OCTA 6*6mm image signal >= 7; d.The basic treatment of vitreous injection was performed for 3 times.

Exclusion criteria

Exclusion criteria: a. Ametropia = + 3.00 D; b. Macular OCTA imaging quality is poor due to opacity of refractive media or difficulty in fixation. If the image signal is less than 7; c. Patients with other chorioretinal diseases and fundus hemorrhage; d. Patients with neovascularization or neovascular glaucoma combined with anterior segment (including iris and chamber angle); e. The study eye has active ocular inflammation or there is evidence of infectious blepharitis, keratitis, scleritis or conjunctivitis in any eye.; f. A history of external injuries to the eye or any previous intraocular surgery other than cataract surgery; g. Previous photodynamic therapy, laser photocoagulation, vitreous cavity anti-VEGF therapy; h. Other patients that the researchers believe need to be excluded.

Design outcomes

Primary

MeasureTime frame
Retinal pigment epithelial detachment;

Secondary

MeasureTime frame
subretinal hyperreflective material;best-corrected visual acuity;central subfield thickness;Sub-foveal choroidal thickness;

Countries

China

Contacts

Public ContactJie Zhong

Sichuan Academy of Medical Sciences Sichuan Provincial People's Hospital

zhongjie@med.uestc.edu.cn+86 138 0806 3276

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026